Llwytho...
Anti-tumor antibodies can drive therapeutic T cell responses
The classical view of therapeutic monoclonal antibodies against tumor associated antigens is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Trends Cancer |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5657573/ https://ncbi.nlm.nih.gov/pubmed/28867165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trecan.2017.07.001 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|